Recombinant human interleukin-35 and its preparation method and application

By employing a Knobs-into-Holes (KIH) structure design in recombinant human interleukin-35, the problem of unstable binding between the EBI3 and p35 subunits was solved, enabling efficient expression and purification of recombinant IL-35 and providing a new therapeutic approach for cancer, immune diseases, and inflammatory diseases.

CN117986386BActive Publication Date: 2024-11-29KANGLITAI BIOMEDICAL (QINGDAO) CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410167256.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-06
Publication Date
2024-11-29
Estimated Expiration
2044-02-06

AI Technical Summary

Technical Problem

Existing technologies struggle to effectively express and purify bioactive recombinant human interleukin-35 (IL-35), especially due to the instability of the heterodimer caused by the non-covalent binding of the EBI3 and p35 subunits, which affects its secretion and activity in cells.

Method used

Using a Knobs-into-Holes (KIH) structure design, the EBI3 and p35 subunits are covalently bound through the KIH structure to ensure the stability and bioactivity of the heterodimer. Recombinant human interleukin-35 is expressed and purified in host cells by constructing a recombinant vector.

Benefits of technology

This study achieved efficient expression and purification of recombinant human interleukin-35, ensuring its biological activity and providing new research ideas and therapeutic approaches, particularly its potential applications in cancer, immune diseases, and inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117986386B_ABST
    Figure CN117986386B_ABST
Patent Text Reader

Abstract

The present application relates to the field of biomedical technology, and in particular to a recombinant human interleukin-35 and its preparation method and application. The recombinant human interleukin-35 has human interleukin-35 biological activity, and is a heterodimer of a first fusion polypeptide and a second fusion polypeptide; from the N-terminus to the C-terminus, the first fusion polypeptide includes a first active peptide and a first auxiliary peptide shown in SEQ ID NO.11, and the second fusion polypeptide includes a second active peptide and a second auxiliary peptide shown in SEQ ID NO15, and the first auxiliary peptide and the second auxiliary peptide form a KIH structure. The present application provides a recombinant IL-35 having a KIH structure. Based on the KIH structure, EBI3 and p35 can be covalently bound to form a heterodimer, and therefore have good biological activity, providing a new idea for subsequent expression and activity research of such cytokines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine technology, and in particular to a recombinant human interleukin-35 and a preparation method and application thereof. Background Art

[0002] IL-12 family members are all important cytokines, and are heterodimers composed of α chains (p19, p28, p35) and β chains (p40 and EBI3). Interleukin-35 (IL-35) is a member of the IL-12 cytokine family. It has a similar structure to other members of the IL-12 family (IL-12, IL-23, IL-27, IL-39). It is a heterodimer composed of Epstein-Barr virus-induced gene 3 (EBI3) and IL-12 p35, and is mainly secreted by regulatory T cells (Tregs) and regulatory B cells (Bregs).

[0003] As an anti-inflammatory and immunosuppressive cytokine, IL-35 can play an important role in the occurrence and development of various inflammatory reactions and autoimmune diseases by regulating the differentiation and function of T cells, B cells, dendritic cells and macrophages. The results also showed that IL-35 is closely related to a variety of human diseases, including infectious diseases, sepsis, autoimmune diseases, inflammation and tumors. Therefore, IL-35 is expected to become a new biomarker reflecting disease progression and prognosis, or as a new target for disease treatment, with broad clinical treatment prospects.

[0004] IL-12 p35 contains 7 cysteines, and EBI3 contains 4 cysteines. The two subunits of IL-12 p35 and EBI3 can bind to each other through non-covalent bonds to form heterodimers. At the same time, the subunits themselves can also bind to form p35:p35 or EBI3:EBI3 homodimers or even multimers. The receptor of IL-35 is a dimer composed of IL-12Rβ2 and gp130, which shares the receptor chain with IL-12 and IL-27. IL-35 transmits signals through heterodimers or homodimers composed of IL-12Rβ2 and gp130, and produces different biological effects depending on the composition of the receptor. Although IL-35 homodimers or polymers may still contribute to in vivo immunosuppression during information transmission, this weaker non-covalent binding and unclear subunit combination form lead to many difficulties in the expression of human IL-35, and some studies have speculated that due to the interaction between EBI3 and p35 in cells, homodimeric hIL-35 cannot be effectively secreted from transfected cells.

[0005] At present, some studies have tried to purify recombinant biologically active IL-35 from Escherichia coli, but no active IL-35 can be obtained. CN116478926A records the following scheme: a dual plasmid expression system with human interleukin 35 gene (the natural nucleotide sequence of p35 subunit is synthesized on pXC17.4 plasmid, and the natural nucleotide sequence of EBI3 subunit is synthesized on pcDNA3.1 plasmid) is transiently transfected into the genome of CHO K1 cells. After multiple screening tests and biological activity tests, a cell line with high expression of human interleukin 35 is finally screened, which increases the expression of IL-35. However, since the molecules after expression still have homodimers and polymers, it is difficult to purify and obtain highly pure IL-35 protein with biological activity. There are also studies that attempt to design IL-35 into a heterodimeric protein covalently linked to EBI3 and p35. The activity of the obtained rhIL-35 is not stable, which may be affected by the spatial position of the binding of EBI3 and p35. There are also attempts to construct a fusion protein of Fc fragment and IL-35, but the biological activity of the resulting recombinant IL-35 needs to be improved. The traditional technical solutions for constructing a fusion protein of Fc fragment and IL-35 are described in the invention patent application CN106075401A and the master's thesis "Study on the eukaryotic expression and biological function of recombinant human interleukin-35", in which:

[0006] CN106075401A records the amino acid sequences of EBI3, P35, linker and fusion proteins of synthetic IL-35. The synthetic IL-35 fusion protein is obtained by linking the Fc of human IgG1 at the C-terminus of IL-35. The advantage of Fc fusion protein is that part of the antigenic peptide of the pathogen can be fused with the IgG-Fc fragment, inducing the body to produce an antigen-specific immune response and enhancing the disease resistance of IL-35. In the invention, a single plasmid is transfected into Expi293E cells, and the cell suspension is collected on the 6th day of transfection. The obtained cell suspension is centrifuged at high speed, and the IL-35 in the supernatant is concentrated after ultrafiltration with a 0.45μm filter after discarding the cell debris. The concentrated liquid passes through a liquid exchange device and is eluted to obtain an IL-35 fusion protein without impurity peaks. The IL-35 fusion protein is successfully expressed by comparing it with the positive control protein.

[0007] "Study on the eukaryotic expression and biological function of recombinant human interleukin-35" describes the construction of IL-35 (EBI3+Linker+P35)

[0008] The eukaryotic expression vector pSTEP2-IL35-Fc was transfected into HEK293T cells and cultured in a 10L reactor for 7 days. The supernatant was harvested and purified using a protein affinity chromatography column to obtain recombinant human IL-35-Fc protein. The protein expression was identified by SDS-PAGE and Western Blot, and the biological activity of rhIL-35 was detected. Summary of the invention

[0009] Based on this, one or more embodiments of the present application provide a recombinant human interleukin-35 and a preparation method and application thereof, including the following technical solutions:

[0010] One or more embodiments of the present application provide a recombinant human interleukin-35, which has human interleukin-35 biological activity and is a heterodimer of a first fusion polypeptide and a second fusion polypeptide;

[0011] From N-terminus to C-terminus,

[0012] The first fusion polypeptide includes the first active peptide shown in SEQ ID NO.11 and the first auxiliary peptide,

[0013] The second fusion polypeptide includes a second active peptide shown in SEQ ID NO 15 and a second auxiliary peptide,

[0014] The first auxiliary peptide and the second auxiliary peptide form a KIH structure.

[0015] In some embodiments of the present application, the recombinant human interleukin-35 satisfies one or more of the following conditions:

[0016] (1) The first active peptide and the first auxiliary peptide are directly connected;

[0017] (2) the second active peptide and the second auxiliary peptide are directly connected; and,

[0018] (3) The first helper peptide and the second helper peptide are each independently selected from mutant peptides of an antibody Fc fragment.

[0019] In some embodiments of the present application, the first auxiliary peptide and the second auxiliary peptide are each independently selected from a mutant peptide of an IgG antibody Fc fragment.

[0020] In some embodiments of the present application, a signal peptide is further connected to the N-terminus of the first fusion polypeptide and the second fusion polypeptide.

[0021] In some embodiments of the present application, the N-terminus of the signal peptide is also connected to a first protease cleavage site fragment.

[0022] In some embodiments of the present application, the C-termini of the first fusion polypeptide and the second fusion polypeptide are each independently connected to a second protease cleavage site fragment.

[0023] One or more embodiments of the present application also provide a nucleic acid molecule encoding the recombinant human interleukin-35.

[0024] One or more embodiments of the present application also provide a recombinant vector, which includes the nucleic acid molecule.

[0025] One or more embodiments of the present application also provide a recombinant cell that expresses the recombinant human interleukin-35.

[0026] One or more embodiments of the present application also provide a method for constructing the recombinant cell, which comprises the step of introducing the nucleic acid molecule into a host cell to construct the recombinant cell.

[0027] One or more embodiments of the present application also provide a method for preparing the recombinant human interleukin-35, which comprises the following steps:

[0028] culturing the recombinant cell; and,

[0029] The recombinant human interleukin-35 is isolated from the obtained culture.

[0030] One or more embodiments of the present application also provide a use of the recombinant human interleukin-35, the nucleic acid molecule, the recombinant vector or the recombinant cell in the preparation of a drug for treating cancer, autoimmune diseases or inflammatory diseases.

[0031] One or more embodiments of the present application also provide a drug, which includes the recombinant human interleukin-35, the nucleic acid molecule, the recombinant vector or the recombinant cell, and a pharmaceutically acceptable carrier.

[0032] Compared with the traditional technology, the beneficial effects of this application include:

[0033] The present application provides a recombinant IL-35 having a KIH structure. Based on the KIH structure, EBI3 and p35 can covalently bind to form a heterodimer, and thus has excellent biological activity (including good binding with gp130 and promoting PBMCs cell proliferation), providing a new idea for subsequent expression and activity studies of such cytokines. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In order to more clearly illustrate the technical solutions in the embodiments of the present application and to more completely understand the present application and its beneficial effects, the following is a brief introduction to the drawings required for the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application, and those skilled in the art can obtain other drawings based on these drawings without creative work.

[0035] Figure 1 The results of the Dot Blot test for IL-35 concentration in the cell supernatant 96 hours after plasmid transfection in Example 1;

[0036] Figure 2 This is the SDS-PAGE image of KIH-IL-35 after purification in Example 2;

[0037] Figure 3 This is the Western Blot identification result diagram in Example 3;

[0038] Figure 4 This is a diagram showing the activity identification results of KIH-IL-35 in Example 4;

[0039] Figure 5 This is a graph showing the results of the study on the activity of KIH-IL-35 against PBMCs in Example 5. DETAILED DESCRIPTION

[0040] The present application will be further described in detail below in conjunction with the accompanying drawings, embodiments and examples. It should be understood that these embodiments and examples are only used to illustrate the present application and are not used to limit the scope of the present application. The purpose of providing these embodiments and examples is to make the understanding of the disclosure of the present application more thorough and comprehensive. It should also be understood that the present application can be implemented in many different forms, is not limited to the embodiments and examples described herein, and those skilled in the art can make various changes or modifications without violating the connotation of the present application, and the equivalent form obtained also falls within the protection scope of the present application. In addition, in the description below, a large number of specific details are given in order to provide a more comprehensive understanding of the present application, and it should be understood that the present application can be implemented without one or more of these details.

[0041] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing implementation modes and embodiments and are not intended to limit this application.

[0042] the term

[0043] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0044] The terms "and / or", "or / and", and "and / or" used in this article include any one of two or more related listed items, and also include any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").

[0045] In the present application, "plurality", "multiple", "multiple times", "multiples", etc., unless otherwise specified, refer to a number greater than 2 or equal to 2. For example, "one or more" means one or greater than or equal to two.

[0046] As used herein, "combination thereof", "any combination thereof", "any combination thereof" etc. include all suitable combinations of any two or more of the listed items.

[0047] Herein, the “suitable” mentioned in “suitable combination”, “suitable method”, “any suitable method”, etc., shall be based on the ability to implement the technical solution of this application, solve the technical problems of this application, and achieve the expected technical effects of this application.

[0048] Herein, “preferred”, “better”, “more preferred” and “suitable” are merely used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute limitations on the scope of protection of this application.

[0049] In the present application, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present application.

[0050] In this application, "optionally", "optional", and "optional" mean optional or dispensable, that is, any one of the two parallel schemes of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent.

[0051] In the present application, the terms "first", "second", "third", "fourth", etc. in "the first aspect", "the second aspect", "the third aspect", "the fourth aspect", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.

[0052] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0053] In the present application, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to the integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In this article, it is equivalent to directly listing each integer, such as t is an integer selected from 1 to 10, indicating that t is any integer selected from the integer group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all sub-ranges included therein.

[0054] The temperature parameters in this application, unless otherwise specified, are allowed to be either constant temperature treatment or to vary within a certain temperature range. It should be understood that the constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. Fluctuations within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are allowed.

[0055] In the present application, %(w / w) and wt% both refer to weight percentage, %(v / v) refers to volume percentage, and %(w / v) refers to mass volume percentage.

[0056] Over the past decade, more and more studies have shown that IL-35 plays an important role in controlling immune-related diseases, including autoimmune diseases, infectious diseases, and cancer. However, a comprehensive understanding of IL-35 still faces some obstacles. For example, the production of purified untagged rIL-35 remains a major challenge that limits its functional analysis. Another important unresolved issue is how to maintain and regulate the stability of heterodimers in vivo. As our understanding of IL-35 biology increases, it may be discovered that IL-35 has other functions besides inhibiting T cell proliferation, but whether IL-35 has other functions remains to be determined. As a drug research, it is crucial to obtain correctly expressed proteins. However, there are currently no stable related IL-35 products that can be used for scientific research or commercial-scale production.

[0057] This application relies on the classic Knobs-into-holes to ensure that the two subunits of IL-35 are expressed and assembled and matured separately, reducing the generation of mismatched by-products, attempting to produce correctly assembled recombinant cytokines, and further verifying the biological properties of the recombinant cytokines. This study provides a new idea for the expression and activity research of such cytokines.

[0058] Knobs-into-Holes (KIH) is essentially a technology based on steric hindrance to promote heavy chain heterodimerization, which can solve the problem of mismatching of heterologous antibody heavy chains. The KIH structure was first proposed by Crick in 1953 as a packing model of amino acid side chains in the α-helix. In 1996, John BB Ridgway and his colleagues at Genentech developed and proved that the KIH technology for the assembly of bispecific antibody heavy chains was effective in promoting the correct assembly of antibodies. In this technology, the first technical platform for the assembly of bispecific antibody heavy chains was realized by replacing small amino acids with large amino acids (such as T366W) and inserting them into the "Hole" (large amino acids are replaced by small amino acids). Studies have found that although mutations in the CH3 domain (such as T366Wk (knob) and T366Sh, L368Ah and Y407Vh (hole)) will also produce a small amount of homodimer complexes, more products are heterodimer complexes, which are generally more favorable for the formation of heterodimer complexes. At the same time, this method is suitable for expressing glycosylated proteins in eukaryotic expression systems or bacterial expression systems.

[0059] The first aspect of the present application

[0060] The present application embodiment provides a recombinant human interleukin-35, which has human interleukin-35 biological activity and is a heterodimer of a first fusion polypeptide and a second fusion polypeptide;

[0061] From N-terminus to C-terminus,

[0062] The first fusion polypeptide includes the first active peptide shown in SEQ ID NO.11 and the first auxiliary peptide,

[0063] The second fusion polypeptide includes a second active peptide shown in SEQ ID NO 15 and a second auxiliary peptide,

[0064] The first auxiliary peptide and the second auxiliary peptide form a KIH structure.

[0065] The KIH structure, also known as the knob-and-hole structure, is a structure in which the polypeptide chains form a protruding "Knobs" structure and a concave "Holes" structure in space, and the "Knobs" structure and the "Holes" structure bite into each other to form the KIH structure.

[0066] In some examples, the first active peptide and the first auxiliary peptide are directly connected. In some examples, the second active peptide and the second auxiliary peptide are directly connected.

[0067] "Direct connection" is relative to "indirect connection", which means that the two fused polypeptides are not connected through an intermediate medium such as a flexible chain, but the amino group at the N-terminus of one polypeptide and the carboxyl group at the C-terminus of the other polypeptide are directly dehydrated and condensed to form a peptide bond, and the two polypeptides are connected through a peptide bond.

[0068] Based on the understanding of the "KIH structure", it can be understood that under the condition that the first auxiliary peptide and the second auxiliary peptide can form a KIH structure and ensure that the resulting recombinant human interleukin-35 has the biological activity of human interleukin-35, the present application can be not particularly limited to the first auxiliary peptide and the second auxiliary peptide, and the first auxiliary peptide and the second auxiliary peptide can be independently selected but not limited to the mutant peptide of the antibody Fc fragment. In the process of forming the "KIH structure", the first auxiliary peptide can have a "Knobs" type structure and the second auxiliary peptide can have a "Holes" type structure, or vice versa, that is, the first auxiliary peptide has a "Holes" type structure and the second auxiliary peptide has a "Knobs" type structure. It can be understood that the "antibody Fc fragment" in the mutant peptide of the antibody Fc fragment, which specifically includes the hinge region, CH2 region and CH3 region in the present application, can be a natural antibody Fc fragment, or it can be an antibody Fc fragment artificially modified on the basis of the natural antibody Fc fragment, for example, an antibody Fc fragment shown in any one of SEQ ID NO.21 to SEQ ID NO.29. The following specific examples use the antibody Fc fragment shown in SEQ ID NO.29 as an example to construct its mutant peptide to explain the technical solution of the present application. It should be understood that the present application is not limited thereto.

[0069] Optionally, relative to the antibody Fc fragment, the mutation site of the mutant peptide of the antibody Fc fragment is located in the CH3 region. In some embodiments, the mutation site of the mutant peptide of the antibody Fc fragment includes a mutation of T in its CH3 region to W to form a "Knobs" type structure to form one of the first auxiliary peptide and the second auxiliary peptide, and the mutation site of the mutant peptide of the antibody Fc fragment includes a mutation of T in its CH3 region to S, L to A, and Y to V to form a "Holes" type structure to form the other of the first auxiliary peptide and the second auxiliary peptide.

[0070] The present application does not specifically limit the type of mutant peptides of the antibody Fc fragment, and can be selected from but not limited to the mutant peptides of the IgG antibody Fc fragment. It is understandable that the present application does not specifically limit the mutant peptides of the IgG antibody Fc fragment, for example: it can be a mutant peptide of the IgG1 antibody Fc fragment, it can also be a mutant peptide of the natural IgG2 antibody Fc fragment, it can also be a mutant peptide of the natural IgG3 antibody Fc fragment, or it can be a mutation of the natural IgG4 antibody Fc fragment. The sequences of the CH3 regions of different antibody Fc fragments are different, and the mutation sites are also different accordingly. For example, the Fc fragment shown in SEQ ID NO.29, after T366W mutation to form a "Knobs" type structure, thereby corresponding to the formation of one of the first auxiliary peptide and the second auxiliary peptide (optionally the first auxiliary peptide), after T366S, L368A and Y407V mutation to form a "Holes" type structure, thereby corresponding to the formation of the first auxiliary peptide and the other of the second auxiliary peptide (optionally the second auxiliary peptide). The mutant peptides of the antibody Fc fragment in the present application include but are not limited to the auxiliary peptide combinations shown in SEQ ID NO.13 and SEQ ID NO.17 and SEQ ID NO.30 and SEQ ID NO.31. The following examples of the present application take a group of auxiliary peptides shown in SEQ ID NO.13 and SEQ ID NO.17 as an example to explain the technical solution of the present application, and it is understood that the present application is not limited thereto.

[0071] In some examples, a signal peptide is further connected to the N-terminus of the first fusion polypeptide and the second fusion polypeptide.

[0072] The term "signal peptide" refers to a fragment that guides the secretion of biologically active molecule drugs and fusion proteins, and is cut off after translation in the host cell. The characteristics of signal peptides are well known in the art, and signal peptides generally have 16 to 30 amino acids, but they may contain a greater or lesser number of amino acid residues. Conventional signal peptides consist of three regions: a basic N-terminal region, a central hydrophobic region, and a more polar C-terminal region. The central hydrophobic region includes 4 to 12 hydrophobic residues, which fix the signal peptide through the membrane lipid bilayer during the translocation of the immature polypeptide. After initiation, the signal peptide is usually cut off in the lumen of the ER by a cellular enzyme called a signal peptidase. Specifically, the signal peptide can be a secretory signal peptide of tissue plasminogen activation (tPa), a signal peptide of herpes simplex virus glycoprotein D (HSV gDs), or growth hormone. Alternatively, a secretory signal peptide used in higher eukaryotic cells including mammals and the like can be used. In addition, as a secretory signal peptide, a signal peptide contained in wild-type IL-7 can be used, or it can be used after replacing a codon with a high expression frequency in a host cell. The signal peptide of the present application can be selected from but not limited to the signal peptide shown in SEQ ID NO.19, the signal peptide shown in SEQ ID NO.1 from 1 to 20, and the signal peptide shown in SEQ ID NO.3 from 1 to 22, and can be optionally the signal peptide shown in SEQ ID NO.19. Further, the N-terminus of the signal peptide is also connected to a first protease cleavage site fragment, including but not limited to KL. In one example, the C-terminus of the first fusion polypeptide and the second fusion polypeptide is also connected to a second protease cleavage site fragment, including but not limited to EF.

[0073] The second aspect of the embodiment of the present application

[0074] The embodiment of the present application provides a nucleic acid molecule encoding the recombinant human interleukin-35.

[0075] Optionally, the nucleic acid molecule of the present application includes the nucleic acid molecule shown in positions 70 to 1383 of SEQ ID NO. 8 and the nucleic acid molecule shown in positions 70 to 1347 of SEQ ID NO. 10. Furthermore, the nucleic acid molecule may further include one or more of a nucleic acid molecule encoding a signal peptide, a nucleic acid molecule encoding the first protease cleavage site, and a nucleic acid molecule encoding a second protease cleavage site.

[0076] The "nucleic acid molecule encoding a signal peptide" of the present application is a polynucleotide encoding an amino acid sequence that initiates the movement of a protein through the endoplasmic reticulum (ER) membrane.

[0077] The third aspect of the present application

[0078] The embodiment of the present application provides a recombinant vector, which includes the nucleic acid molecule.

[0079] "Expression system" or "expression vector (or vector)" refers to a nucleic acid sequence containing the desired coding sequence and control sequence in an operable connection so that the host transformed with these sequences can produce the encoded protein. To achieve transformation, the expression system can be contained on a vector; however, the relevant nucleic acid molecule can also be subsequently integrated into the host chromosome.

[0080] In some examples, the recombinant vector includes a first recombinant vector and a second recombinant vector.

[0081] Among the first recombinant vector and the second recombinant vector, one recombinant vector includes the nucleic acid molecule shown at positions 70 to 1383 in SEQ ID NO.8, and one recombinant vector includes the nucleic acid molecule shown at positions 70 to 1347 in SEQ ID NO.10.

[0082] In some examples, the first recombinant vector and the second recombinant vector are each independently selected from pXC17.4 plasmid or pcDNA3.1(+).

[0083] In some examples, the first recombinant vector is pcDNA3.1(+) and includes the nucleic acid molecules shown at positions 70 to 1383 in SEQ ID NO.8, and the second recombinant vector is pXC17.4 plasmid and includes the nucleic acid molecules shown at positions 70 to 1347 in SEQ ID NO.10.

[0084] The fourth aspect of the embodiment of the present application

[0085] The present application embodiment provides a recombinant cell, which expresses the recombinant human interleukin-35.

[0086] In some examples, the cell includes a eukaryotic cell. In some examples, the cell is an animal cell. In some examples, the animal cell is a mammalian cell. In some examples, the source of the mammalian cell includes a mouse, including but not limited to a hamster. In some examples, the mammalian cell includes but is not limited to an ovarian cell, such as a CHO-K1 cell.

[0087] A fifth aspect of the present application

[0088] The embodiment of the present application provides a method for constructing a recombinant cell, which includes the step of introducing the nucleic acid molecule into a host cell to construct a recombinant cell.

[0089] Optionally, the construction method comprises: constructing the recombinant vector; and transfecting the host cell with the recombinant vector to construct the recombinant cell.

[0090] "Introduction", "transfer", "transfection", "stable transfer" or "transient transfection" refers to the uptake of the expression vector by the host cell, regardless of whether any coding sequence is actually expressed. A variety of transfection methods are known to those skilled in the art. For example, transfection is accomplished in the presence of an expression vector and a high concentration of calcium phosphate, by electroporation, by using a bacteriophage or viral expression vector to insert into a host cell, by mechanical insertion of nucleic acids, or even by culturing host cells in the presence of unpackaged nucleic acid fragments. Transfection success is usually confirmed when any indication of the manipulation of the vector of interest appears in the host cell.

[0091] The sixth aspect of the embodiment of the present application

[0092] The present application embodiment provides a method for preparing recombinant human interleukin-35, which comprises the following steps:

[0093] culturing the recombinant cell; and,

[0094] The recombinant human interleukin-35 is isolated from the obtained culture.

[0095] It is understandable that the culture is carried out under conditions suitable for the recombinant cells, and different types of recombinant cells may have different corresponding culture conditions (optimal culture medium, temperature, pH, etc.).

[0096] The seventh aspect of the embodiment of the present application

[0097] The embodiments of the present application provide a use of the recombinant human interleukin-35, the nucleic acid molecule, the recombinant vector or the recombinant cell in the preparation of a drug for treating cancer, immune diseases or inflammatory diseases.

[0098] "Cancer" generally refers to the presence of cells with typical characteristics of oncogenic cells (such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features). Cancer cells are usually observed to aggregate into tumors, but such cells can exist alone in animal subjects, or can be non-tumorigenic cancer cells, such as leukemia cells. Therefore, the term "cancer" can encompass references to solid tumors, soft tissue tumors, or metastatic lesions. As used herein, the term "cancer" includes precancerous and malignant cancers, including but not limited to hepatocellular carcinoma, human lung adenocarcinoma, Hodgkin's lymphoma, acute myeloid leukemia, esophageal cancer, pancreatic ductal adenocarcinoma, cervical cancer, and colorectal cancer.

[0099] Immune diseases are diseases caused by imbalance of immune regulation that affects the body's immune response. In a broad sense, immune diseases also include structural or functional abnormalities of the immune system caused by congenital or acquired reasons, including but not limited to psoriasis, lupus erythematosus, immune diabetes, autoimmune uveitis, and rheumatoid arthritis.

[0100] Inflammatory diseases generally include autoinflammatory diseases and inflammatory diseases caused by infection with other pathogenic microorganisms. Inflammatory diseases include but are not limited to ulcerative colitis, lupus nephritis and neuroinflammation.

[0101] The eighth aspect of the embodiment of the present application

[0102] The embodiment of the present application provides a drug, which includes the recombinant human interleukin-35 and a pharmaceutically acceptable carrier.

[0103] The medicine of the application can be suitable for the medicine used for injection, including sterile aqueous solution (water soluble) or dispersion, and the sterile powder for the temporary preparation of sterile injectable solution or dispersion.For intravenous administration, suitable carrier includes physiological saline, antibacterial water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).In all cases, the medicine should be sterile and should be the fluid that is easy to inject.It should be stable under manufacturing and storage conditions and must resist the contamination of microorganisms (such as bacteria and fungi) and preserve.Carrier can be solvent or dispersion medium, and the solvent or dispersion medium contain such as water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol etc.) and its suitable mixture.For example, can by using coating such as lecithin, by maintaining required particle size and by using surfactant (for example, sodium lauryl sulfate) in the case of dispersion, maintain suitable fluidity. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.). In many cases, isotonic agents, such as sugars, polyols (such as mannitol, sorbitol), and / or sodium chloride will generally be included in the composition. Prolonged absorption of injectable compositions can be achieved by including an agent that delays absorption (e.g., aluminum monostearate and gelatin) in the composition.

[0104] Sterile injectable solutions can be prepared by incorporating the active ingredient in the desired amount into a suitable solvent optionally with one or a combination of the ingredients listed above, followed by sterilization filtration. Typically, dispersions are prepared by incorporating the active ingredient into a sterile vehicle containing a basic dispersion medium and other ingredients required from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred preparation methods are vacuum drying and freeze drying, which produce a powder of the active ingredient plus any additional required ingredients from a previously sterile filtered solution.

[0105] In some cases, the medicine of the present application is prepared with a carrier that protects the active ingredient from being rapidly eliminated from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. Such formulations can be prepared using standard techniques. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies for viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art.

[0106] A ninth aspect of the embodiments of the present application

[0107] An embodiment of the present application provides a method for alleviating cancer, immune diseases or inflammatory diseases, the method comprising administering to the subject the recombinant human interleukin-35 described in the first aspect, the nucleic acid molecule described in the second aspect, the vector described in the third aspect, the recombinant cell described in the fourth aspect or the drug described in the eighth aspect.

[0108] In this application, "alleviate" and "prevent and / or treat" have the same meaning and can be used interchangeably. In this application, "alleviate" includes aspects such as prevention, treatment, and adjuvant therapy. As used herein, "alleviate" means to alleviate, delay the progression, attenuate, prevent, or maintain an existing disease or condition. "Alleviate" also includes curing one or more symptoms of a disease or condition, preventing its development, or alleviating it to a certain extent.

[0109] In the present application, the subject is a mammal. In some examples, the mammal is a human or a mouse.

[0110] For the definitions of cancer, immune diseases, and inflammatory diseases, please refer to the definition in aspect 7.

[0111] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0112] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0113] Example 1. Expression of IL-35 recombinant protein

[0114] In this example, a recombinant expression plasmid of IL-35 fused with KIH structure (KIH-IL-35) was constructed, transfected into CHO-K1 cells and cultured for 96 hours, and the supernatant was collected for purification to determine the best method. The specific process is as follows:

[0115] 1. Construction of KIH-IL-35 expression plasmid

[0116] The natural nucleotide and amino acid sequences of human p35 and EBI3 were retrieved from the NCBI online database: the amino acid sequence of the EBI3 subunit is shown in SEQ ID NO.1, and the nucleotide sequence is shown in SEQ ID NO.2; the amino acid sequence of the P35 subunit is shown in SEQ ID NO.3, and the nucleotide sequence is shown in SEQ ID NO.4. In addition, the amino acid sequence and nucleotide sequence of the signal peptide are shown in SEQ ID NO.5 and SEQ ID NO.6.

[0117] Based on IgG4Fc, the sequences of peptide chain P35-Fch (hole) and peptide chain EBI3-Fck (knob) were designed and optimized using T366W (knob) and T366S, L368A and Y407V (hole) mutations, and BGI was commissioned to synthesize the plasmids, of which P35-Fch was constructed in pXC17.4 plasmid and EBI3-Fck was constructed in pcDNA3.1(+). The amino acid sequence of EBI3-Fck is shown in SEQ ID NO.7, and the optimized nucleotide sequence is shown in SEQ ID NO.8; the amino acid sequence of P35-Fch is shown in SEQ ID NO.9, and the optimized nucleotide sequence is shown in SEQ ID NO.10.

[0118] Then, the pXC17.4-EBI3-Fck and pcDNA3.1(+)-p35-Fch vectors were constructed by restriction digestion and ligation. The pcDNA3.1(+) and pXC17.4 empty plasmids were linearized using EcoR Ⅰ and Hind Ⅲ and the linearized vectors were recovered by gel electrophoresis. The pcDNA3.1(+)-EBI3-Fck and pXC17.4-p35-Fch were digested with the same endonucleases and the target fragments were recovered by gel electrophoresis and then connected with the linearized vectors using DNA ligase to obtain pXC17.4-EBI3-Fck and pcDNA3.1(+)-p35-Fch.

[0119] 2. Amplification of plasmid

[0120] (1) Plasmid transformation: ① Take 100 μL of DH5α competent bacteria, add an appropriate amount of plasmid DNA prepared in step 1 on ice, mix gently, place on ice for 20 min, heat shock at 32°C for 90 s, and place on ice for 3 min; ② Add 200 μL LB medium, shake and culture at 37°C at 150 rpm for 1 h, take an appropriate amount of bacterial solution and spread it on an LB medium plate containing ampicillin, and culture at 37°C overnight.

[0121] (2) Screening and identification of clones: ① Streak the strain on an LB medium (containing ampicillin) plate and culture at 37°C overnight; ② After the colonies grow the next day, select a single and round plaque, pick it out with a gun tip, and add it to 1 mL of liquid LB medium containing ampicillin resistance, and culture it in a shaker at 37°C at 220 rpm for 4 h. Add 10 μL of the culture solution to 100 mL of liquid LB medium containing ampicillin resistance, and culture it in a shaker at 37°C at 220 rpm for 12-16 h.

[0122] (3) Endotoxin-free extraction of recombinant expression plasmid (using the Norwegian Extraction Kit): 1). Take 100 mL of overnight cultured bacterial solution, centrifuge at about 11,000 rpm (12,000 × g) for 1-2 minutes, discard the supernatant, and collect the bacteria. 2). Add 7.5 mL of Buffer P1 containing RNase A to the centrifuge tube with the bacterial pellet, and mix by pipetting or vortexing. 3). Add 7.5 mL of Buffer P2 to the bacterial suspension prepared in step 2), gently invert up and down 6-8 times to mix, and let it stand at room temperature for 4-5 minutes. 4). Add 7.5 mL of Buffer P4 to the bacterial suspension prepared in step 3), and immediately gently invert up and down 6-8 times to allow the solution to completely neutralize Buffer P2. At this time, a white flocculent precipitate should appear. Centrifuge at a speed of greater than about 10,000rpm (11,000×g) for 10-15min, and carefully pipette the supernatant into a new 50 mL round-bottom tube to avoid pipetting the floating white precipitate. 5). Add 0.1 times the volume (10% of the volume of the supernatant, about 2.2mL) of endotoxin remover to the supernatant obtained in step 4), invert and mix, place in an ice bath or insert in crushed ice (or refrigerator freezer) for 5 minutes until the solution changes from turbid to clear and transparent (or still slightly turbid), and mix occasionally several times in the middle. 6). Place in a 37℃ water bath for 10-15min, the solution quickly becomes turbid again, and invert and mix. 7). Centrifuge at room temperature at about 11,000rpm (12,000×g) for 10 minutes to separate the phases (the temperature must be greater than 25℃). The upper aqueous phase contains DNA, and the lower blue oily phase contains endotoxin and other impurities. Transfer the upper aqueous phase containing DNA to a new tube and discard the oily layer. 8). Add 0.5 times the volume of isopropanol (about 10 mL) to the upper aqueous phase, mix thoroughly by inversion, transfer to the adsorption column several times (the adsorption column is placed in the collection tube), centrifuge at about 11,000 rpm (12,000 × g) for 1 min, and pour out the waste liquid in the collection tube. Until all the mixed solution passes through this adsorption column. 9). Add 10 mL of rinse solution PW with anhydrous ethanol, about 11,000 rpm (12,000 × g), and discard the waste liquid. Put the adsorption column back into the collection tube, add 10 mL of rinse solution PW, and repeat the rinse once. 10). Use a pipette tip to remove any ethanol that may remain between the inner ring and the column wall, put the adsorption column back into the empty collection tube, centrifuge at the highest speed for 3 minutes to dry the residual ethanol on the matrix membrane, open the lid and dry at room temperature for 3-5 minutes. 11). Take out the adsorption column and put it into a clean centrifuge tube. Add 1-2 mL of Buffer TB preheated at 55°C to the middle part of the adsorption membrane. Leave it at room temperature for 3 minutes. Centrifuge at about 11,000 rpm (12,000×g) for 3 minutes to elute the plasmid. After the plasmid is sterilized by membrane, store it at -20°C.

[0123] 3. Transient transfection recovery CHO-K1 cells were subcultured and adapted to culture. When the cell growth state returned to normal, preparations for transfection were started. Observe and select cells that are in the logarithmic growth phase and growing well, and inoculate 30mL into a shake flask at 3×106 cells / well. FectoPRO transfection reagent (Polyplus Transfection) was used to prepare transfection complexes at a ratio of 1:2 of plasmid: FectoPRO (µg / µL). After incubation at room temperature for 10 minutes, the transfection complexes were added to the cells in the above shake flasks and the supernatant was collected after 96 days of culture.

[0124] The CHO-K1 cell culture medium was: EmCD CHO medium (Eminence) + 1% H / T (Gibco) + 0.5% Anti-clumping Agent (Gibco) + 6mM L-glutamine (Gibco); the transfection medium was Opti-MEM (Gibco). The cell culture conditions were 37°C, 5% CO2, suspension culture, rotation speed was 110rpm, the initial culture cell density was 3×105cell / mLcell / mL-5×105cell / mL, and the cells were passaged every 2-4 days.

[0125] 4. Dot Blot Detection of IL-35 in Cell Supernatant

[0126] ① Loading: Cut the transfer filter membrane of appropriate size according to the number of samples, add 20μL of cell supernatant to the transfer membrane twice, and dry it in the fume hood; ② Blocking: Add 20mL 5% milk-PBST to immerse, place on a shaker at room temperature for 90min; after blocking, pour out the milk, and wash three times with 10mL PBST shaker, 5min each time. ③ Blocking: Block with 5% skim milk prepared in advance, and block on a shaker for 1h; ④ Incubate with primary antibody: After blocking, incubate with primary antibody at 4℃ overnight. The primary antibody is Human / Mouse IL-12 / IL-35 p35 antibody or anti-IL-27 / IL-35 EBI3 antibody, and the antibody is diluted with PBST at a concentration of 1:1000. After washing the NC membrane with the prepared 1×PBST buffer overnight, rinse it 3 times, 10min each time; ⑤ Incubate with secondary antibody: secondary antibody Goat anti Mouse HRP (Genscript), diluted with PBST at 1:1000. Incubate at room temperature for 45 minutes, discard the antibody, and wash three times with PBST, 5 minutes each time;⑥Exposure: Prepare the exposure substrate in the ratio of A liquid: B liquid = 1:1. Take out the membrane and dry it slightly, then place it on a thin layer of plastic film. Add the freshly prepared exposure substrate and react in the dark for 2 minutes before color development.

[0127] result: Figure 1Dot Blot was used to detect the concentration of IL-35 in the cell supernatant 96 hours after plasmid transfection. Figure 1 As shown in the figure, Dot blot analysis showed that the expression of pcDNA3.1-EBI3-Fck was lower than that of pXC17.4-p35-Fch and the expression of the replaced vector combination ( Figure 1 middle right figure), so the original expression vector was selected for subsequent experiments.

[0128] Example 2. Purification of KIH-IL-35 recombinant protein

[0129] The expression supernatant collected in Example 1 was collected, centrifuged at 5000rpm for 10min, and the supernatant was filtered using a 0.22μm filter to obtain a supernatant free of impurities such as cell debris. The Protein A affinity chromatography column was pre-washed with buffer A (1×PBS) for 5-10 CV to balance the column, the sample was loaded within the column pressure range, and the impurities were washed again with buffer A, and the elution peak was collected by elution with 0.1M Gly-HCl at pH 3.0. The eluate was immediately adjusted to neutral with NaOH or tris, and ultrafiltered and concentrated using a 3K ultrafiltration tube. Finally, SDS-PAGE was used for verification.

[0130] Polyacrylamide gel electrophoresis, refer to the fifth method of electrophoresis in 0541 of the 2020 edition of the four pharmacopoeias, SDS-polyacrylamide gel electrophoresis (SDS-PAGE method):

[0131] 1. Sample handling

[0132] Mix the test sample with the reducing or non-reducing buffer at a volume ratio of 3:1, and mix thoroughly on a vortex shaker for electrophoresis. Before loading the test sample and physicochemical reference substance for reduced SDS-PAGE, heat them in a water bath or a 100℃ metal bath heater for 5 minutes and cool them to room temperature.

[0133] Non-reducing buffer (4×): weigh 3.03 g of tris(hydroxymethyl)aminomethane, 20 mg of bromophenol blue, 8.0 g of sodium dodecyl sulfate, measure 40 mL of glycerol, dissolve in water and dilute to about 80 mL, adjust the pH to 6.8 with hydrochloric acid, and dilute to 100 mL with water.

[0134] Reducing buffer (4×): Weigh 3.03 g of tris(hydroxymethyl)aminomethane, 20 mg of bromophenol blue, 8.0 g of sodium dodecyl sulfate, measure 40 mL of glycerol, dissolve in water and dilute to about 80 mL, add 20 mL of β-mercaptoethanol, adjust the pH to 6.8 with hydrochloric acid, and dilute to 100 mL with water.

[0135] 2. Sample loading and electrophoresis

[0136] 2.1 After the concentrated gel is polymerized, carefully pull out the sample comb, fix the homemade gel on the electrophoresis device, put the electrophoresis tank on ice, and add the diluted 1× electrode buffer to the inner and outer tanks. Fill the inner tank of the electrophoresis tank. The buffer in the outer tank should not cover the inner tank and should not be less than 2 / 3 of the inner tank.

[0137] 2.2 Add the centrifuged samples and markers to the gel wells in a predetermined order. The total amount of protein loaded should be more than 10 μg. Be cautious during the protein loading operation to avoid overflow of the test sample into the adjacent lanes to prevent cross contamination and loss of the test sample.

[0138] 2.3 After loading, connect the electrophoresis device to the power supply, ensure that the positive and negative poles of the power supply are correct, turn on the power supply of the electrophoresis tank, and perform constant voltage electrophoresis. The initial voltage is 80V, and it is adjusted to 120-140V when entering the separation gel. Bromophenol blue is used as an electrophoresis indicator band. The gel running time should ensure that the sample is effectively separated and does not run out of the gel. After the electrophoresis is completed, remove the gel, gently pry open the glass plate, remove the gel and put it into the staining box, stain it with staining solution for 20 minutes, decolorize it with destaining solution for 2 hours, and then image it.

[0139] result: Figure 2 This is the SDS-PAGE picture of KIH-IL-35 after purification. Figure 2 The results showed that there was a clear band at 120-150 kD under non-reducing buffer treatment, indicating that the KIH structure can effectively promote the formation of IL-35 dimers; under reducing buffer treatment conditions, there was a uniform band at around 70 kD, which was consistent with the expected size.

[0140] Example 3. Western-Blot Identification and Detection of KIH-IL-35

[0141] ① Sample treatment: mix the sample with 4× reducing buffer (same as in Example 2), and heat at 100°C for 5 min, or mix the sample with 4× non-reducing buffer (same as in Example 2); ② Electrophoresis: divided into two steps: first adjust the constant voltage of the electrophoresis instrument to 80V, run electrophoresis for about 20 min, and when the sample runs to the separation gel visually, adjust the voltage to 120V. After judging that the target protein is fully separated, the electrophoresis can be ended; ③ Transfer: take out the glass plate and slowly pry open the glass plate with a gel plate. Gently take out the gel and soak it in transfer buffer; cut the PVDF membrane of appropriate size and soak it in methanol for 1-2 minutes for activation; after the protective papers on both sides of the PVDF membrane are completely soaked, put the PVDF membrane into the transfer buffer for soaking and rinsing, and fully soak two transfer sponge pads and filter paper at the same time; put them in the order of black plate-fiber pad-filter paper-gel-PVDF membrane-filter paper-fiber pad-white plate, and use a glass rod to gently roll away excess bubbles for each layer to prevent bubbles from affecting the transfer effect; clamp the plate and put it into the transfer instrument, adjust the constant current to 200mA, and adjust the transfer time according to the size of the protein; ④ Blocking: After the transfer is completed, rinse the PVDF membrane with PBS for 10 minutes and block it with 5% skim milk powder at room temperature on a shaker for 2 hours; ⑤ Primary antibody incubation: The primary antibody is Human / Mouse IL-12 / IL-35 p35 antibody or anti-IL-27 / IL-35 EBI3 antibody, and the antibody is diluted at 1:2500 The concentration was diluted with PBST and incubated overnight at 4°C; ⑤ Secondary antibody incubation: After overnight incubation, remove the PVDF membrane and rinse it with PBST for 3 times at room temperature, 10 minutes each time; dilute the secondary antibody (Goat anti Mouse HRP (Genscript)) with PBST, immerse the PVDF membrane in the secondary antibody incubation solution, and incubate it on a shaker at room temperature for 2 hours; ⑥ Washing the membrane: After the secondary antibody incubation is completed, wash the PVDF membrane with PBST for 3 times, 10 minutes each time; then wash it with TBS for 3 times, 10 minutes each time; ⑦ Chemiluminescence and imaging: Use the ECL color development kit (BIO-RED), mix the A solution and the B solution in equal proportions and add them to the centrifuge tube, wrap it with tin foil to avoid light, and shake it up and down to mix. When developing, carefully place the rinsed PVDF membrane face up in a clean large dish, evenly add an appropriate amount of ECL developer, place it on the ImageQuant LAS 4000 mini imager chassis, open the supporting software, adjust the focus and exposure time, and image to obtain the protein immunoblot chemical development map.

[0142] result: Figure 3 The Western Blot results are shown in Table 1. Figure 3The results showed that the non-reduced and reduced results were consistent with expectations when KIH-IL-35 was detected using Human / Mouse IL-12 / IL-35 p35 antibody and anti-IL-27 / IL-35 EBI3 antibody, respectively. There was a clear band at 120-150 kD under non-reduced buffer treatment, indicating that the KIH structure can effectively promote the formation of IL-35 dimers; under reduced buffer treatment conditions, there was a uniform band at around 70 kD, which corresponded to the SDS-PAGE gel electrophoresis results.

[0143] Example 4. Activity detection of KIH-IL-35 recombinant protein

[0144] 1. Principle

[0145] The receptor of IL-35 is composed of IL-12β2 and gp130. The gp130 molecule is one of the receptors of interleukin 6. The biological activity of IL-6 is mediated by its receptor IL-6R and gp130, which transmit the signal of IL-6 into the cell. IL-6 can induce mouse myeloid leukemia cells (mouse M1 cells) to stop growing, differentiate, and eventually apoptosis. Based on this, it can be inferred that if it can bind to its receptor chain gp130, it will inhibit the biological effect of IL-6. According to the signal transduction of IL-6, after KIH-IL-35 binds to free gp130, IL-6 can bind to free IL-6R and continue to bind to the gp130 receptor on the cell membrane to transmit signals normally, inhibiting mouse leukemia M1 cells; if KIH-IL-35 cannot bind to free gp130, free gp130 will block the complex formed by the binding of IL-6 and IL-6R during the culture process, but will have no effect on mouse leukemia M1 cells. Therefore, different concentrations of IL-35 were added to IL-6-stimulated M1 cells to detect the inhibitory effect of IL-35 on IL-6.

[0146] 2. Methods

[0147] ① Cell culture: M1 mouse myeloid leukemia cells were cultured in RPMI1640 medium containing 10% fetal bovine serum at 37°C and 5% CO2 until the logarithmic growth phase for use in experiments.

[0148] ②Activity detection: Dilute mouse leukemia M1 cells to 4×105cell / mL cell suspension containing 200ng / mL IL-6, 100ng / mL IL-6R, and 800ng / mL gp130, and add to 96-well cell culture plates at 50μL / well; dilute KIH-IL-35 with RPMI-1640 medium (containing dual antibody P / S) + 10% FBS medium, and add to the cell culture plate at 50μL / well, with the first well at 6000ng / mL, three-fold gradient dilution, a total of 8 gradients. Use the culture medium as a blank control. The 96-well culture plate was placed in a 37°C, 5% CO2 incubator; after 96 hours of cell culture, 10% of the total volume, i.e., 10 μL CCK-8, was added to each well and cultured in a 37°C incubator for 3-4 hours. The absorbance value at OD450nm was measured, and the cell proliferation inhibition rate was calculated according to the following formula: Cell proliferation inhibition rate (%) = [(blank group-experimental group) / blank group] × 100%. The data were processed using the four-parameter method: GraphPad Prism 6 software was used to process the data, with OD value as the ordinate and dilution concentration as the abscissa, and four parameters were used for fitting to obtain the activity curve, EC50 value, and R2 value. The test standard requires R2 value ≧0.95.

[0149] Biological activity is y = (AD) / [1+(x / C)B]+D

[0150] Note:

[0151] y: OD value;

[0152] x: concentration of rhIL-18;

[0153] A: represents the upper limit of absorbance, which represents the upper asymptote of the S-shaped curve;

[0154] B: absorbance increase rate parameter, equivalent to the slope of the curve;

[0155] C: The concentration value at which the absorbance growth rate begins to change, i.e., the EC50 value of rhIL-18;

[0156] D: represents the lower limit of absorbance, representing the lower asymptote of the S-shaped curve.

[0157] result: Figure 4 The results of the activity identification of KIH-IL-35 are shown in Figure 1. The results show that as the concentration of rhIL-35 increases, the inhibition rate of M1 mouse leukemia cells also increases. The EC50 value obtained by processing the data using the four-parameter method is 1913 ng / mL.

[0158] Example 5. Study on the activity of KIH-IL-35 recombinant protein against PBMCs

[0159] PBMCs cells were induced and cultured with anti-CD3 and anti-CD28 mAbs at a concentration of 500 ng / mL, and 5 μL each of CD3 and CD56 flow cytometry antibodies were added after treatment. Cells without antibody addition were used as blank controls.

[0160] The activated PBMCs were diluted to a cell suspension of 1×106cell / mL and added to a 96-well cell culture plate at 50μL / well. KIH-IL-35 was diluted with Dayu N500 medium and added to the cell culture plate at 50μL / well, with the first well being 6000ng / mL, and three-fold gradient dilutions, for a total of 8 gradients. KIH-IL-35 was gradiently diluted with Dayu N500 medium and added to the cell culture plate at 50μL / well, with the medium as a blank control. The 96-well culture plate was placed in a 37°C, 5% CO2 incubator; after 96 hours of cell culture, 10% of the total volume, i.e., 10μL CCK-8 reagent, was added to each well, and the cells were cultured in a 37°C incubator for 3h-4h, and the absorbance value at OD450nm was measured.

[0161] result: Figure 5 This is the result of the study on the activity of KIH-IL-35 on PBMCs. The flow cytometry results of PBMCs cells after 17 days of induction culture showed that the proportion of CD3+CD56+ cells was 75.86%. The results of activating the activity of PBMCs cells showed that with the increase of KIH-IL-35 concentration, the OD value of the detection gradually increased, that is, the increase of KIH-IL-35 concentration promoted the proliferation of PBMCs cells after induction culture, and the EC50 value of the effect was 5552ng / mL.

[0162] Sequence 1 (SEQ ID NO.1) is the amino acid sequence of signal peptide 1-EBI3:

[0163] MTPQLLLALVLWASCPPCSG|RKGPPAALTLPRVQCRASRYPIAVDCSWTLPPAPNSTSPVSFIATYRLGM

[0164] AARGHSWPCLQQTPTSTSCTITDVQLFSMAPYVLNVTAVHPWGSSSSFVPFITEHIIKPDPPEGVRLSPLAERQLQVQWEPPGSWPFPEIFSLKYWIRYKRQGAARFHRVGPIEATSFILRAVRPRARYYVQVAAQDLTDYGELSDWSLPATATMSLGK.

[0165] Sequence 2 (SEQ ID NO.2) is the nucleotide sequence of signal peptide 1-EBI3-stop codon:

[0166] ATGACTCCACAACTACTACTAGCACTAGTGCTGTGGGCCTCTTGTCCTCCATGCTCTGGC|AGAAAG

[0167] GGCCCTCCAGCCGCTCTGACACTGCCCAGAGTGCAGTGCCGCGCTTCCCGGTATCCTATCGCCGTGGACTGCTCCTGGACACTGCCTCCTGCCCCTAACTCCACCTCTCCCGTGTCCTTTATCGCCACCTACCGGCTGGGCATGGCCGCCAGAGGCCATTCTTGGCCTTGCCTGCAGCAGACCCCTACATCTACCTCCTGTACCATCACCGATGTGCAGCTGTTCTCCATGGCTCCTTACGTGCTGAACGTGACCGCCGTGCACCCTTGGGGCAGCTCCAGCTCCTTCGTGCCTTTTATCACCGAGCACATCATCAAGCCTGATCCCCCCGAAGGAGTCAGACTGTCTCCCCTGGCCGAAAGACAGCTGCAAGTGCAGTGGGAGCCTCCAGGATCTTGGCCTTTCCCTGAGATCTTCAGCCTGAAGTACTGGATCAGATACAAGCGGCAGGGCGCTGCTCGGTTCCACAGAGTGGGCCCCATTGAGGCCACCAGCTTCATCCTGAGAGCCGTGCGGCCTAGAGCTAGATACTACGTCCAGGTGGCCGCCCAGGACCTGACCGACTACGGCGAGCTGTCCGACTGGTCCCTGCCTGCTACCGCTACCATGTCTCTCGGCAAA|TGA。

[0168] Sequence 3 (SEQ ID NO.3) is the amino acid sequence of signal peptide 2-P35:

[0169] MCPARSLLLVATLVLLDHLSLA|RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEI

[0170] DHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS。

[0171] Sequence 4 (SEQ ID NO.4) is the nucleotide sequence of signal peptide 2-P35:

[0172] ATGTGCCCAGCACGAAGTCTACTACTAGTGGCTACCCTGGTGCTGCTCGATCATCTGTCCCTGGCT|A

[0173] GAAACCTGCCTGTGGCTACCCCTGATCCTGGCATGTTCCCTTGCTTGCACCACAGCCAGAACCTGCTGAGAGCCGTGTCCAACATGCTGCAGAAGGCCAGACAGACCCTGGAGTTCTACCCCTGTACCTCTGAGGAAATCGACCACGAGGACATCACCAAGGACAAGACATCTACCGTGGAGGCCTGCCTGCCTCTGGAACTGACCAAGAACGAGTCCTGTCTGAACTCCAGAGAGACCAGCTTCATCACCAATGGCTCCTGCCTGGCTTCTCGGAAGACATCCTTCATGATGGCCCTGTGCCTGTCTTCCATCTACGAGGATCTGAAGATGTACCAGGTGGAATTTAAGACCATGAACGCCAAACTGCTGATGGACCCCAAGCGGCAGATCTTCCTGGACCAAAACATGCTGGCTGTGATCGACGAGCTGATGCAGGCTCTGAACTTCAACTCCGAGACCGTGCCACAGAAAAGCTCTCTGGAAGAGCCTGACTTCTATAAGACCAAGATCAAGCTCTGCATCCTGCTGCACGCCTTTCGGATCAGAGCCGTCACAATTGACCGCGTGATGTCCTACCTGAATGCCTCC。

[0174] Sequence 5 (SEQ ID NO.5) is the amino acid sequence of signal peptide 3: ATMGWSCIILFLVATATGVHS。

[0175] Sequence 6 (SEQ ID NO.6) is the nucleotide sequence of signal peptide 3:

[0176] GCCACCATGGGCTGGAGCTGCATCATCCTGTTCCTGGTGGCCACCGCCACCGGCGTGCACAGC.

[0177] Sequence 7 (SEQ ID NO.7) is the amino acid sequence of restriction site-signal peptide 3-EBI3-Fck-restriction site:

[0178] KL|ATMGWSCIILFLVATATGVHS|RKGPPAALTLPRVQCRASRYPIAVDCSWTLPPAPNSTSPVSFIATYR

[0179] LGMAARGHSWPCLQQTPTSTSCTITDVQLFSMAPYVLNVTAVHPWGSSSSFVPFITEHIIKPDPPEGVRLSPLAERQLQVQWEPPGSWPFPEIFSLKYWIRYKRQG AARFHRVGPIEATSFILRAVRPRARYYVQVAAQDLTDYGELSDWSLPATATMSLGK|AESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS

[0180] QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEM TKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG|EF.

[0181] Sequence 8 (SEQ ID NO.8) is the nucleotide sequence of restriction site-signal peptide 3-EBI3-Fck-restriction site:

[0182] AAGCTT|GCCACCATGGGCTGGTCCTGCATTATCCTGTTTCTGGTGGCCACCGCCACCGGCGTTCATT

[0183] CC|AGGAAAGGACCTCCTGCTGCTCTGACCCTGCCTAGGGTGCAGTGTAGAGCTTCCAGGTATCCCA

[0184] TTGCTGTGGACTGTTCCTGGACACTGCCCCCTGCTCCTAATTCCACATCCCCCGTGTCCTTTATCGCCACATACAGGCTGGGCATGGCCGCCAGAGGACATTCCTGGCCTTGTCTGCAACAAACACCCACATCCACCTCCTGCACCATCACCGACGTTCAGCTGTTTTCCATGGCCCCCTATGTGCTGAACGTGACCGCTGTGCACCCTTGGGGATCTTCCTCCTCCTTTGTGCCTTTCATCACCGAGCACATCATCAAGCCCGACCCCCCCGAAGGAGTGAGGTTGTCCCCTTTGGCTGAGAGGCAACTGCAAGTGCAATGGGAACCCCCTGGCTCCTGGCCTTTTCCTGAAATTTTTTCCCTGAAGTACTGGATCAGGTACAAGAGGCAGGGCGCCGCCAGGTTTCATAGGGTGGGACCTATCGAGGCCACATCCTTTATCCTGAGGGCCGTGAGGCCCAGGGCTAGGTATTATGTGCAAGTGGCCGCTCAGGACCTGACCGACTATGGCGAACTGTCCGATTGGTCCCTGCCCGCTACAGCTACAATGTCCCTGGGAAAA|GCTGAATCCAAATACGGCCCTCCTTGCCCCCCTTGTCCTGCTCCTG

[0185] AAGCTGCTGGAGGACCTTCCGTTTTTCTGTTCCCTCCTAAACCCAAAGACACCCTGATGATCTCCAGGACCCCCGAGGTTACATGTGTGGTGGTGGATGTGTCCCAGGAGGACCCCGAAGTGCAATTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCTAAGACAAAGCCCAGGGAGGAGCAGTTTAACTCCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCATCAAGACTGGCTGAATGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCTCCTCCATTGAGAAGACCATCTCCAAGGCCAAGGGCCAGCCCAGGGAACCTCAAGTGTATACCCTGCCCCCTTCCCAGGAGGAAATGACCAAAAATCAGGTGTCCCTGTGGTGCCTGGTGAAGGGCTTTTATCCCTCCGACATCGCCGTGGAGTGGGAGTCCAATGGCCAACCCGAAAATAACTACAAGACCACCCCCCCCGTGCTGGACTCCGATGGATCTTTTTTTCTGTACTCCAGGCTGACCGTGGACAAGTCCAGGTGGCAAGAAGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCATAATCACTACACCCAGAAATCCCTGTCCCTGTCCCTGGGC|GAATTC。

[0186] Sequence 9 (SEQ ID NO.9) is the amino acid sequence of restriction enzyme site - signal peptide 3 - P35 - Fch - restriction enzyme site:

[0187] KL|ATMGWSCIILFLVATATGVHS|RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSE

[0188] EIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS|AESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNW

[0189] YVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG|EF。

[0190] Sequence 10 (SEQ ID NO.10) is the nucleotide sequence of restriction enzyme site - signal peptide 3 - P35 - Fch - restriction enzyme site:

[0191] AAGCTT|GCCACCATGGGCTGGTCCTGCATCATTCTGTTCCTGGTGGCCACCGCCACCGGCGTGCAT

[0192] TCC|AGGAACTTGCCTGTGGCTACCCCCGATCCTGGAATGTTTCCCTGTCTGCACCATTCCCAAAAC

[0193] CTGCTGAGGGCCGTGTCCAACATGCTGCAGAAAGCCAGGCAGACCCTGGAGTTTTACCCCTGCACATCCGAGGAGATCGACCACGAGGATATCACCAAGGACAAGACCTCCACCGTGGAGGCCTGCCTGCCTCTGGAACTGACAAAAAATGAATCCTGCCTGAACTCCAGGGAAACCTCCTTCATCACCAACGGCTCCTGCCTGGCCTCTAGGAAAACATCCTTTATGATGGCCCTGTGCCTGTCCTCCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGAGGCAGATTTTCCTGGACCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACTCCGAAACCGTGCCCCAAAAGTCCTCCCTGGAGGAACCTGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGGATCAGGGCCGTGACTATTGATAGGGTGATGTCCTACCTGAACGCCTCC|GCCGAATCC

[0194] AAGTACGGCCCTCCTTGTCCCCCTTGTCCTGCTCCTGAAGCTGCCGGAGGACCTTCCGTGTTTCTGTTCCCCCCTAAACCTAAAGACACCCTGATGATCTCCAGGACCCCCGAGGTTACATGCGTGGTGGTGGATGTGTCCCAAGAGGACCCCGAAGTGCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCTAAGACAAAGCCCAGGGAGGAGCAGTTCAACTCCACCTACAGGGTGGTGTCCGTGCTGACCGTTCTGCATCAGGATTGGCTGAATGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCTCCTCTATTGAGAAAACCATTTCCAAGGCCAAGGGCCAGCCCAGGGAACCCCAAGTTTATACACTGCCCCCTTCCCAAGAAGAGATGACCAAAAACCAGGTGTCCCTGTCCTGCGCCGTGAAGGGATTTTATCCCTCCGACATTGCCGTGGAGTGGGAGTCCAATGGACAGCCCGAAAATAACTACAAGACCACCCCCCCCGTGCTGGACTCCGATGGATCCTTTTTTCTGGTGTCCAGGCTGACCGTGGACAAGTCCAGGTGGCAAGAGGGAAATGTGTTCTCCTGTTCCGTGATGCACGAGGCCCTGCACAATCACTATACCCAGAAGTCCCTGTCCCTGTCCCTGGGC|GAATTC。

[0195] Sequence 11 (SEQ ID NO.11) is the amino acid sequence of EBI3:

[0196] RKGPPAALTLPRVQCRASRYPIAVDCSWTLPPAPNSTSPVSFIATYRLGMAARGHSWPCLQQTPTSTSCTITDVQLFSMAPYVLNVTAVHPWGSSSSFVPFITEHIIKPDPPEGVRLSPLAERQLQVQWEPPGSWPFPEIFSLK

[0197] YWIRYKRQGAARFHRVGPIEATSFILRAVRPRARYYVQVAAQDLTDYGELSDWSLPATATMSLGK。

[0198] Sequence 12 (SEQ ID NO.12) is the nucleotide sequence of optimized EBI3:

[0199] AGGAAAGGACCTCCTGCTGCTCTGACCCTGCCTAGGGTGCAGTGTAGAGCTTCCAGGTATCCCATTGCTGTGGACTGTTCCTGGACACTGCCCCCTGCTCCTAATTCCACATCCCCCGTGTCCTTTATCGCCACATACAGGCTGGGCATGGCCGCCAGAGGACATTCCTGGCCTTGTCTGCAACAAACACCCACATCCACCTCCTGCACCATCACCGACGTTCAGCTGTTTTCCATGGCCCCCTATGTGCTGAACGTGACCGCTGTGCACCCTTGGGGATCTTCCTCCTCCTTTGTGCCTTTCATCACCGAGCACATCATCAAGCCCGACCCCCCCGAAGGAGTGAGGTTGTCCCCTTTGGCTGAGAGGCAACTGCAAGTGCAATGGGAACCCCCTGGCTCCTGGCCTTTTCCTGAAATTTTTTCCCTGAAGTACTGGATCAGGTACAAGAGGCAGGGCGCCGCCAGGTTTCATAGGGTGGGACCTATCGAGGCCACATCCTTTATCCTGAGGGCCGTGAGGCCCAGGGCTAGGTATTATGTGCAAGTGGCCGCTCAGGACCTGACCGACTATGGCGAACTGTCCGATTGGTCCCTGCCCGCTACAGCTACAATGTCCCTGGGAAAA。

[0200] Sequence 13 (SEQ ID NO.13) is the amino acid sequence of Fck:

[0201] AESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG。

[0202] Sequence 14 (SEQ ID NO.14) is the nucleotide sequence of Fck:

[0203] GCTGAATCCAAATACGGCCCTCCTTGCCCCCCTTGTCCTGCTCCTGAAGCTGCTGGAGGACCTTCCGTTTTTCTGTTCCCTCCTAAACCCAAAGACACCCTGATGATCTCCAGGACCCCCGAGGTTACATGTGTGGTGGTGGATGTGTCCCAGGAGGACCCCGAAGTGCAATTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCTAAGACAAAGCCCAGGGAGGAGCAGTTTAACTCCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCATCAAGACTGGCTGAATGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCTCCTCCATTGAGAAGACCATCTCCAAGGCCAAGGGCCAGCCCAGGGAACCTCAAGTGTATACCCTGCCCCCTTCCCAGGAGGAAATGACCAAAAATCAGGTGTCCCTGTGGTGCCTGGTGAAGGGCTTTTATCCCTCCGACATCGCCGTGGAGTGGGAGTCCAATGGCCAACCCGAAAATAACTACAAGACCACCCCCCCCGTGCTGGACTCCGATGGATCTTTTTTTCTGTACTCCAGGCTGACCGTGGACAAGTCCAGGTGGCAAGAAGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCATAATCACTACACCCAGAAATCCCTGTCCCTGTCCCTGGGC。

[0204] SEQ ID NO.15 is the amino acid sequence of P35:

[0205] RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKN

[0206] ESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS。

[0207] SEQ ID NO.16 is the optimized nucleotide sequence of P35

[0208] AGGAACTTGCCTGTGGCTACCCCCGATCCTGGAATGTTTCCCTGTCTGCACCATTCCCAAAACCTGCTGAGGGCCGTGTCCAACATGCTGCAGAAAGCCAGGCAGACCCTGGAGTTTTACCCCTGCACATCCGAGGAGATCGACCACGAGGATATCACCAAGGACAAGACCTCCACCGTGGAGGCCTGCCTGCCTCTGGAACTGACAAAAAATGAATCCTGCCTGAACTCCAGGGAAACCTCCTTCATCACCAACGGCTCCTGCCTGGCCTCTAGGAAAACATCCTTTATGATGGCCCTGTGCCTGTCCTCCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGAGGCAGATTTTCCTGGACCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACTCCGAAACCGTGCCCCAAAAGTCCTCCCTGGAGGAACCTGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGGATCAGGGCCGTGACTATTGATAGGGTGATGTCCTACCTGAACGCCTCC。

[0209] Sequence 17 (SEQ ID NO.17) is the amino acid sequence of Fch

[0210] AESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG.

[0211] Sequence 18 (SEQ ID NO.18) is the nucleotide sequence of Fch:

[0212] GCCGAATCCAAGTACGGCCCTCCTTGTCCCCCTTGTCCTGCTCCTGAAGCTGCCGGAGGACCTTCCG

[0213] TGTTTCTGTTCCCCCCTAAACCTAAAGACACCCTGATGATCTCCAGGACCCCCGAGGTTACATGCGTGGTGGTGGATGTGTCCCAAGAGGACCCCGAAGTGCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCTAAGACAAAGCCCAGGGAGGAGCAGTTCAACTCCACCTACAGGGTGGTGTCCGTGCTGACCGTTCTGCATCAGGATTGGCTGAATGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCTCCTCTATTGAGAAAACCATTTCCAAGGCCAAGGGCCAGCCCAGGGAACCCCAAGTTTATACACTGCCCCCTTCCCAAGAAGAGATGACCAAAAACCAGGTGTCCCTGTCCTGCGCCGTGAAGGGATTTTATCCCTCCGACATTGCCGTGGAGTGGGAGTCCAATGGACAGCCCGAAAATAACTACAAGACCACCCCCCCCGTGCTGGACTCCGATGGATCCTTTTTTCTGGTGTCCAGGCTGACCGTGGACAAGTCCAGGTGGCAAGAGGGAAATGTGTTCTCCTGTTCCGTGATGCACGAGGCCCTGCACAATCACTATACCCAGAAGTCCCTGTCCCTGTCCCTGGGC。

[0214] Sequence 19 (SEQ ID NO.19) is the nucleotide sequence 1 of the optimized signal peptide 3:

[0215] GCCACCATGGGCTGGTCCTGCATTATCCTGTTTCTGGTGGCCACCGCCACCGGCGTTCATTCC。

[0216] Sequence 20 (SEQ ID NO.20) is the nucleotide sequence 2 of the optimized signal peptide 3:

[0217] GCCACCATGGGCTGGTCCTGCATCATTCTGTTCCTGGTGGCCACCGCCACCGGCGTGCATTCC。

[0218] Sequence 21 (SEQ ID NO.21) is the amino acid sequence of the Fc of IGG4 (P01861-1) (secreted; sIgG4):

[0219] ESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK. Among them: positions 1 to 12 are hinge regions, positions 13 to 122 are CH2, and positions 123 to 229 are CH3.

[0220] Sequence 22 (SEQ ID NO.22) is the amino acid sequence of Fc of IGG4 (P01861-2):

[0221] ESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLEL. Among them: positions 1 to 12 are hinge regions, positions 13 to 122 are CH2, and positions 123 to 229 are CH3.

[0222] Sequence 23 (SEQ ID NO. 23) is the amino acid sequence of Fc of IGG1 (P01857-1) (secretory; sIgG1):

[0223] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK. Among them: positions 1 to 12 are hinge regions, positions 13 to 125 are CH2, and positions 126 to 232 are CH3.

[0224] Sequence 24 (SEQ ID NO.24) is the amino acid sequence of Fc of IGG1 (P01857-2):

[0225] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPEL. Among them: positions 1 to 12 are hinge regions, positions 13 to 125 are CH2, and positions 126 to 232 are CH3.

[0226] Sequence 25 (SEQ ID NO. 25) is the amino acid sequence of Fc of IGG2 (P01859-1) (secretory; sIgG2):

[0227] ERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK. Among them: positions 1 to 12 are hinge regions, positions 13 to 121 are CH2, and positions 122 to 228 are CH3.

[0228] Sequence 26 (SEQ ID NO.26) is the amino acid sequence of Fc of IGG2 (P01859-2):

[0229] ERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPEL. Among them: positions 1 to 12 are hinge regions, positions 13 to 121 are CH2, and positions 122 to 228 are CH3.

[0230] Sequence 27 (SEQ ID NO. 27) is the amino acid sequence of Fc of IGG3 (P01860-1) (secretory; sIgG3):

[0231] ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPG. Among them: positions 1 to 62 are hinge regions, positions 63 to 172 are CH2, and positions 173 to 278 are CH3.

[0232] Sequence 28 (SEQ ID NO.28) is the amino acid sequence of Fc of IGG3 (P01860-2):

[0233] ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPE. Among them: positions 1 to 62 are hinge regions, positions 63 to 172 are CH2, and positions 173 to 278 are CH3.

[0234] Sequence 29 (SEQ ID NO.29) is the amino acid sequence of Fc of IGG4:

[0235] AESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG. Among them: positions 1 to 13 are hinge regions, positions 14 to 123 are CH2, and positions 124 to 229 are CH3.

[0236] Sequence 30 (SEQ ID NO.30) is the amino acid sequence of the IGG1 antibody Fc fragment (K chain):

[0237] VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.

[0238] Sequence 31 (SEQ ID NO.31) is the amino acid sequence of the IGG1 antibody Fc fragment (H chain):

[0239] VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLEASRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGK.

[0240] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0241] The above-described embodiments only express several implementation methods of the present application, which is convenient for understanding the technical solution of the present application in detail, but it cannot be understood as a limitation on the scope of protection of the patent application. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present application, several deformations and improvements can be made, which all belong to the protection scope of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, the technicians in this field can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by the technicians in this field through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the protection scope of the claims attached to the present application. Therefore, the protection scope of the patent of the present application shall be based on the content of the attached claims, and the description and drawings can be used to explain the content of the claims.

Claims

1. Recombinant human interleukin-35, which has human interleukin-35 biological activity and is a heterodimer of a first fusion polypeptide and a second fusion polypeptide; From N-terminus to C-terminus, The first fusion polypeptide includes the first active peptide shown in SEQ ID NO.11 and the first auxiliary peptide, The second fusion polypeptide includes a second active peptide shown in SEQ ID NO 15 and a second auxiliary peptide, The first auxiliary peptide and the second auxiliary peptide form a KIH structure; The amino acid sequence of the first auxiliary peptide is shown in SEQ ID NO.13, The amino acid sequence of the second auxiliary peptide is shown in SEQ ID NO.17; The first active peptide and the first auxiliary peptide are directly connected; The second active peptide and the second auxiliary peptide are directly connected.

2. The recombinant human interleukin-35 according to claim 1, wherein The N-termini of the first fusion polypeptide and the second fusion polypeptide are independently connected to a signal peptide.

3. The recombinant human interleukin-35 according to claim 2, wherein The N-terminus of the signal peptide is also connected to a first protease cleavage site fragment.

4. The recombinant human interleukin-35 according to claim 2, wherein The C-termini of the first fusion polypeptide and the C-termini of the second fusion polypeptide are each independently connected to a second protease cleavage site fragment.

5. A nucleic acid molecule encoding the recombinant human interleukin-35 according to any one of claims 1 to 4. A recombinant vector comprising the nucleic acid molecule according to claim 5 .

7. A recombinant cell expressing the recombinant human interleukin-35 according to any one of claims 1 to 4.

8. The method for constructing a recombinant cell according to claim 7, comprising the step of introducing the nucleic acid molecule according to claim 5 into a host cell to construct a recombinant cell.

9. The method for preparing recombinant human interleukin-35 according to any one of claims 1 to 4, comprising the following steps: Cultivating the recombinant cell of claim 7; and, The recombinant human interleukin-35 is isolated from the obtained culture.

10. A drug comprising the recombinant human interleukin-35 according to any one of claims 1 to 4, the nucleic acid molecule according to claim 5, the recombinant vector according to claim 6 or the recombinant cell according to claim 7, and a pharmaceutically acceptable carrier.

Citation Information

Patent Citations

  • Application of interleukin 35 to preparation of drugs used for treating autoimmune dermatoses, therapeutic drug, and IL-35-Fc fusion protein

    CN106075401A

  • Immunomodulatory polypeptides and related compositions and methods

    CN110087672A

  • Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same

    CN110267977A

  • Cell strain capable of efficiently expressing human interleukin-35 as well as preparation method and application of cell strain

    CN116478926A